Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 6Neoplasm Metastasis 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Multiple Myeloma 2Lymphoma, Follicular 2Endometrial Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Thyroid cancer, follicular 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Spinocerebellar Degenerations 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Renal Insufficiency 1Recurrence 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Malignant Solid Neoplasm 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hepatic Insufficiency 1Gallbladder Neoplasms 1Digestive System Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1

Interventions

Cyclophosphamide 15romidepsin 9Whole-Body Irradiation 9fludarabine phosphate 8Vincristine 8Etoposide 8Doxorubicin 8Prednisone 7Peripheral Blood Stem Cell Transplantation 7Mycophenolic Acid 7Brentuximab Vedotin 610-propargyl-10-deazaaminopterin 6Rituximab 5Granulocyte Colony-Stimulating Factor 5Gemcitabine 5Cyclosporine 5denileukin diftitox 4Nivolumab 4Lenalidomide 4mogamulizumab 3Tacrolimus 3Methotrexate 3Immunohistochemistry 3Gene Expression Profiling 3Dexamethasone 3Alemtuzumab 3selinexor 2pembrolizumab 2pegfilgrastim 2liposomal doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, T-Cell, Peripheral × copanlisib × Clear all
NCT02535247 2022-07-08

Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma

Fox Chase Cancer Center

Phase 1/2 Terminated
17 enrolled 7 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡